Immunotherapy in malignant pleural mesothelioma: a long story ended in success

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive and rare disease, mainly due to asbestos exposure, characterized by a poor prognosis. For almost two decades, platinum-based chemotherapy has been the only approved therapeutic regimen for first-line MPM, with an overall survival of 12 months. In the last years, the therapeutic scenario of different tumor types, including MPM, has dramatically changed due to immune checkpoint inhibition. The promising results of this approach have promoted new efforts into clinical research, and many trials investigating novel therapeutic combinations are currently ongoing. The aim of the present review is to provide a comprehensive overview of the most promising immunotherapeutic-based strategies currently under investigation for advanced MPM.

Keywords

Malignant pleural mesothelioma / immunotherapy / immune checkpoint inhibitors / cancer vaccine

References

[1] Milano MT.Malignant pleural mesothelioma: a population-based study of survival.J Thorac Oncol2010;5:1841-8

[2] Beasley MB,Dacic S.Pleural mesothelioma classification update.Virchows Arch2021;478:59-72

[3] Husain AN,Ordóñez NG.Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the international mesothelioma interest group.Arch Pathol Lab Med2018;142:89-108

[4] Viscardi G,Morgillo F.How I treat malignant pleural mesothelioma.ESMO Open2020;4:e000669

[5] Vogelzang NJ,Symanowski J.Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.J Clin Oncol2003;21:2636-44

[6] Zalcman G,Margery J.French cooperative thoracic intergroup (IFCT), bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open- label, phase 3 trial.Lancet2016;387:1405-14

[7] Scagliotti GV,Nowak AK.Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.Lancet Respir Med2019;7:569-80

[8] Davis AP,Clarke SJ,Pavlakis N.Emerging biological therapies for the treatment of malignant pleural mesothelioma.Expert Opin Emerg Drugs2021;26:179-92

[9] Ge Z,Sprengers D.TIGIT, the next step towards successful combination immune checkpoint therapy in cancer.Front Immunol2021;12:699895 PMCID:PMC8339559

[10] Baas P,Nowak AK.First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.Lancet2021;397:375-86

[11] Yap TA,Fujimoto N.Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.Lancet Respir Med2021;2021:S2213260020305154

[12] Okada M,Aoe K.Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, japanese phase ii study in malignant pleural mesothelioma (MERIT).Clin Cancer Res2019;25:5485-92

[13] Calabrò L,Fonsatti E.Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.Lancet Oncol2013;14:1104-11

[14] Calabrò L,di Pietro A.CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?.Cancer Immunol Immunother2015;64:105-12

[15] Calabrò L,Fonsatti E.Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.Lancet Respir Med2015;3:301-9

[16] Maio M,Calabrò L.Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.Lancet Oncol2017;18:1261-73

[17] Calabrò L,D’Incecco A,Aerts J.Immune checkpoint therapy of mesothelioma: pre-clinical bases and clinical evidences.Cytokine Growth Factor Rev2017;36:25-31

[18] Quispel-Janssen J,de Vries JF.Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma.J Thorac Oncol2018;13:1569-76

[19] Hassan R,Nemunaitis JJ.Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial.JAMA Oncol2019;5:351-7 PMCID:PMC6439847

[20] Alley EW,Santoro A.Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.Lancet Oncol2017;18:623-30

[21] Fujimoto N,Kijima T.Clinical efficacy and safety of nivolumab in Japanese patients with malignant pleural mesothelioma: 3-year results of the MERIT study.JTO Clin Res Rep2021;2:100135 PMCID:PMC8474205

[22] Popat S,Dafni U.A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.Ann Oncol2020;31:1734-45

[23] Fennell DA,Ottensmeier C.Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.Lancet Oncol2021;22:1530-40 PMCID:PMC8560642

[24] Topalian SL,Anders RA.Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.Nat Rev Cancer2016;16:275-87 PMCID:PMC5381938

[25] Chen J,Yao Q.The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis.World J Surg Oncol2020;18:150 PMCID:PMC7334852

[26] Arru C,Cossu A.Durvalumab plus tremelimumab in solid tumors: a systematic review.Adv Ther2021;38:3674-93 PMCID:PMC8279985

[27] Calabrò L,Giannarelli D.Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.Lancet Respir Med2018;6:451-60

[28] Calabrò L,Morra A.Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.Lancet Respir Med2021;9:969-76

[29] Scherpereel A,Greillier L.Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.Lancet Oncol2019;20:239-53

[30] Disselhorst MJ,Lalezari F.Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.Lancet Respir Med2019;7:260-70

[31] Scherpereel A,Bautista Y.First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.Lung Cancer2022;167:8-16

[32] Peters S,Cornelissen R.First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.Ann Oncol2022;33:488-99

[33] Wright K.FDA approves nivolumab plus ipilimumab for previously untreated unresectable malignant pleural mesothelioma.Oncology2020;34:502-3

[34] Kaur J,Munn AL,Wei MQ.Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy.Crit Rev Oncol Hematol2021;164:103417

[35] Albittar AA,Glitza Oliva IC.Immunotherapy for melanoma.Adv Exp Med Biol2020;1244:51-68.

[36] Esposito G,Carillio G.Immunotherapy in small cell lung cancer.Cancers2020;12:2522 PMCID:PMC7565004

[37] Ganesh K,Cercek A.Immunotherapy in colorectal cancer: rationale, challenges and potential.Nat Rev Gastroenterol Hepatol2019;16:361-75 PMCID:PMC7295073

[38] Lenis AT,Chamie K.Bladder cancer: a review.JAMA2020;324:1980-91

[39] Forde PM,Sun Z.Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.Nat Med2021;27:1910-20 PMCID:PMC8604731

[40] Nowak AK,Kok P.Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.Lancet Oncol2020;21:1213-23

[41] Kok PS,Hughes B.Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.BMJ Open2022;12:e057663 PMCID:PMC8796233

[42] Ordóñez NG.Value of mesothelin immunostaining in the diagnosis of mesothelioma.Mod Pathol2003;16:192-7

[43] Beatty GL,Maus MV.Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies.Cancer Immunol Res2014;;2:112-20 PMCID:PMC3932715

[44] Wang X.Clinical manufacturing of CAR T cells: foundation of a promising therapy.Mol Ther Oncolytics2016;3:16015 PMCID:PMC4909095

[45] Maus MV,Beatty GL.T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.Cancer Immunol Res2013;1:26-31 PMCID:PMC3888798

[46] Haas AR,O’Hara MH.Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers.Mol Ther2019;27:1919-29 PMCID:PMC6838875

[47] Ghosn M,Zhu A.Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial.Lung Cancer2022;165:1-9 PMCID:PMC9256852

[48] Adusumilli PS,Riviere I.A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab.Cancer Discov2021;11:2768 PMCID:PMC8563385

[49] Schuberth PC,Jensen SM.Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.J Transl Med2013;11:187 PMCID:PMC3751305

[50] Petrausch U,Hagedorn C.Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).BMC Cancer2012;12:615 PMCID:PMC3585825

[51] Curioni A,Hiltbrunner S.A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells.Ann Oncol2019;30:v501

[52] Thayaparan T,Achkova DY.CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.OncoImmunology2017;6:e1363137 PMCID:PMC5706532

[53] Klampatsa A,Davies DM.Intracavitary “T4 immunotherapy” of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.Cancer Lett2017;393:52-9

[54] Al-Taei S,Lester JF.Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma.Lung Cancer2012;77:312-8

[55] Beard RE,Lagisetty KH.Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.J Immunother Cancer2014;2:25 PMCID:PMC4155770

[56] Akbari P,Themeli M,van Beijnum JR.The tumor vasculature an attractive CAR T cell target in solid tumors.Angiogenesis2019;22:473-5 PMCID:PMC6864117

[57] Song Q,Wu XH.Therapeutic cancer vaccines: from initial findings to prospects.Immunol Lett2018;196:11-21

[58] Hegmans JP,Aerts JG,Lambrecht BN.Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells.Am J Respir Crit Care Med2005;171:1168-77

[59] Hegmans JP,Lambers ME.Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.Am J Respir Crit Care Med2010;181:1383-90

[60] Cornelissen R,Maat AP.Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma.Am J Respir Crit Care Med2016;193:1023-31

[61] Belderbos RA,Berardi R.A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell immunotherapy for mesothelioma (DENIM) trial.Transl Lung Cancer Res2019;8:280-5 PMCID:PMC6626859

[62] Liu MA.DNA vaccines: an historical perspective and view to the future.Immunol Rev2011;239:62-84

[63] Yang B,Yang A,Hung CF.DNA vaccine for cancer immunotherapy.Hum Vaccin Immunother2014;10:3153-64 PMCID:PMC4514137

[64] Kreiter S,Selmi A,Sahin U.Tumor vaccination using messenger RNA: prospects of a future therapy.Curr Opin Immunol2011;23:399-406

[65] McNamara MA,Holl EK.RNA-based vaccines in cancer immunotherapy.J Immunol Res2015;2015:794528 PMCID:PMC4668311

[66] Pease DF.Oncolytic viral therapy for mesothelioma.Front Oncol2017;7:179 PMCID:PMC5573749

[67] Msaouel P,Dispenzieri A.Clinical trials with oncolytic measles virus: current status and future prospects.Curr Cancer Drug Targets2018;18:177-87 PMCID:PMC5630504

[68] Eguchi T,Mayor M.Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1.Oncotarget2017;8:77872-82 PMCID:PMC5652821

[69] Zauderer MG,Dao T.A randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma.Clin Cancer Res2017;23:7483-9 PMCID:PMC5732877

[70] Hassan R,Kindler H.Clinical response of live-attenuated, Listeria monocytogenes expressing mesothelin (CRS-207) with chemotherapy in patients with malignant pleural mesothelioma.Clin Cancer Res2019;25:5787-98 PMCID:PMC8132300

[71] Rossini M,Bononi I.New perspectives on diagnosis and therapy of malignant pleural mesothelioma.Front Oncol2018;8:91 PMCID:PMC5891579

[72] Harber J,Pritchard C.Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy.J Immunother Cancer2021;9:e003032 PMCID:PMC8438820

[73] Rijavec E,Barletta G,Genova C.Novel approaches for the treatment of unresectable malignant pleural mesothelioma: a focus on immunotherapy and target therapy (Review).Mol Clin Oncol2022;16:89 PMCID:PMC8892433

[74] Brockwell NK,Kumar B,John T.Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma.Transl Lung Cancer Res2020;9:639-45 PMCID:PMC7354134